Welcome to our dedicated page for Castellum SEC filings (Ticker: CTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Castellum, Inc. filings document a Nevada public company that provides cybersecurity, electronic warfare, software engineering, and related technology services to federal government customers. Its Form 8-K reports cover operating results, contract awards, CMMC Level 2 C3PAO certification, debt retirement, executive employment arrangements, officer appointments, and shareholder communications.
Proxy materials describe annual meeting matters, board elections, stockholder voting procedures, executive compensation, and governance practices. The filings also identify Castellum as an emerging growth company and provide formal disclosure around capital structure, subsidiaries, and material events tied to its defense-focused services business.
Castellum, Inc. (CTM) reported an insider equity award. Chief Financial Officer David T. Bell received 225,000 stock options on November 11, 2025 under the Second Amended 2021 Stock Incentive Plan. The options have a $1.19 exercise price and expire on November 10, 2032. They vest ratably over twenty months, beginning December 1, 2025.
Castellum (CTM) reported an insider equity grant. Chief Operating Officer Andrew Merriman was awarded 275,000 stock options on November 11, 2025 under the Second Amended 2021 Stock Incentive Plan at an exercise price of $1.19 per share. The options vest ratably over twenty months, beginning December 1, 2025, and expire on November 10, 2032. Following the grant, 275,000 derivative securities are beneficially owned directly.
Castellum, Inc. (CTM) reported a director equity grant. On 11/11/2025, director C. Thomas McMillen was granted 100,000 stock options with an exercise price of $1.19 per share under the Second Amended 2021 Stock Incentive Plan.
The options relate to 100,000 shares of common stock, vesting ratably over twenty months commencing December 1, 2025, and expiring on 11/10/2032. Following the grant, 100,000 derivative securities were beneficially owned, held directly. The filing classifies the transaction as an acquisition of derivative securities as compensation for board service.
Castellum, Inc. (CTM) disclosed an insider equity award. Director Bernard S. Champoux was granted 100,000 stock options on 11/11/2025 with an exercise price of $1.19 per share under the Second Amended 2021 Stock Incentive Plan. The options vest ratably over twenty months starting December 1, 2025 and expire on 11/10/2032. The filing lists ownership as Direct (D). This is a routine compensation grant to a board member, not an open‑market purchase or sale.
Castellum, Inc. (CTM) reported an insider equity award. Director Mark S. Alarie received a grant of 100,000 stock options on 11/11/2025 under the Second Amended 2021 Stock Incentive Plan. The options have an exercise price of $1.19 per share and an expiration date of 11/10/2032.
The award was granted as compensation for service on the Board and vests ratably over 20 months starting December 1, 2025. Following the transaction, Mr. Alarie beneficially owned 100,000 stock options, held directly. The option grant price was recorded at $0 as an award (no purchase cost at grant).
Castellum, Inc. (CTM) reported that CEO and President Glen R. Ives received an equity award. On November 11, 2025, he was granted 500,000 stock options with an exercise price of $1.19 per share under the Second Amended 2021 Stock Incentive Plan. The options cover the right to purchase 500,000 shares of common stock, vesting ratably over twenty months starting December 1, 2025, and expiring November 10, 2032.
Castellum, Inc. (CTM) reported an insider equity award. Director John F. Campbell received 100,000 stock options granted on November 11, 2025 under the Second Amended 2021 Stock Incentive Plan at an exercise price of $1.19 per share.
The options are exercisable for 100,000 shares of common stock, vesting ratably over twenty months starting December 1, 2025, and carry an expiration date of November 10, 2032. The grant price for the derivative security is listed as $0 at issuance, and the ownership form is direct.
CTM holder filed a Form 144 to sell up to 800,000 shares of common stock with an aggregate market value of $1,016,000, through First Georgetown Securities, with an approximate sale date of 11/11/2025 on the NYSE.
The shares were acquired on 06/12/2019 via a merger/consolidation. In the past three months, a seller named Jay Wright reported selling 1,279,700 common shares for $1,400,305 in gross proceeds.
Castellum, Inc. (CTM) filed its Q3 2025 10‑Q. The company reported quarterly revenue of $14,619,687, up from $11,608,691 a year ago, and generated net income of $415,401 versus a prior‑year net loss. Gross profit was $5,490,568. Basic and diluted EPS were $0.00 compared with $(0.02) last year.
For the first nine months, revenue totaled $40,308,142 versus $34,466,131 in the prior year, with a smaller year‑to‑date net loss. Operating expenses declined year over year, and income from operations improved to $445,280 in the quarter from a loss in the prior period.
Cash was $17,818,338 at September 30, 2025. Total liabilities decreased to $9,523,811 from $17,655,409 at year‑end, reflecting repayment of the revolving credit facility and reduction of notes payable to $2,000,000. Stockholders’ equity rose to $36,728,812. Shares outstanding were 94,612,750 as of November 6, 2025. The company completed public offerings in March and June 2025 and reported warrant exercises. Three U.S. government customers represented 72% of year‑to‑date revenue.
Castellum, Inc. furnished a Form 8-K to disclose that it issued a press release with financial results for the three months ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The information is provided under Item 2.02 (Results of Operations and Financial Condition) and is furnished, not filed, under the Exchange Act. The report was signed by Chief Executive Officer Glen R. Ives. Castellum’s common stock trades on the NYSE American under the symbol CTM.